Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

INTRODUCTION: Several studies have demonstrated that non-small cell lung cancer patients (NSCLCs) harboring epidermal growth factor receptor (EGFR) mutations have poor clinical outcomes in response to treatment with programmed death-1 (PD-1) inhibitors. However, it remains unclear whether EGFR-mutat...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Cancer Res Clin Oncol
मुख्य लेखकों: Masuda, Ken, Horinouchi, Hidehito, Tanaka, Midori, Higashiyama, Ryoko, Shinno, Yuki, Sato, Jun, Matsumoto, Yuji, Okuma, Yusuke, Yoshida, Tatsuya, Goto, Yasushi, Yamamoto, Noboru, Ohe, Yuichiro
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Springer Berlin Heidelberg 2020
विषय:
Original Article – Clinical Oncology
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7810613/
https://ncbi.nlm.nih.gov/pubmed/32705363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-020-03329-0
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन